LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$1.14
+0.02 (+1.79%)
Open$1.12
Previous Close$1.12
Day High$1.15
Day Low$1.10
52W High$2.09
52W Low$0.95
Volume—
Avg Volume1.02M
Market Cap275.47M
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+3,445.6% upside
Current
$1.14
$1.14
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.52M | 7.77M | 231.61M |
| Net Income | -66,718,014 | -37,268,006 | -65,233,876 |
| Profit Margin | -240.2% | -228.2% | -28.2% |
| EBITDA | -37,720,688 | -22,240,971 | -95,106,936 |
| Free Cash Flow | — | — | -33,113,271 |
| Rev Growth | +61.1% | +61.1% | -6.2% |
| Debt/Equity | 0.00 | 0.00 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |